These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 24526500)

  • 41. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
    Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
    JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of limus-eluting versus paclitaxel-eluting coronary artery stents in patients with diabetes mellitus: A meta-analysis.
    Liu Y; Gao L; Song Y; Chen L; Xue Q; Tian J; Wang Y; Chen Y
    Int J Cardiol; 2015 Apr; 184():680-691. PubMed ID: 25777069
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials.
    Bangalore S; Amoroso N; Fusaro M; Kumar S; Feit F
    Circ Cardiovasc Interv; 2013 Aug; 6(4):378-90. PubMed ID: 23922145
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of 2-year outcomes between zotarolimus-eluting and everolimus-eluting new-generation cobalt-chromium alloy stents in real-world diabetic patients.
    Miyazaki T; Latib A; Panoulas VF; Miyazaki S; Costopoulos C; Sato K; Naganuma T; Kawamoto H; Daida H; Colombo A
    Catheter Cardiovasc Interv; 2015 Jul; 86(1):E11-8. PubMed ID: 25534499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of paclitaxel-eluting stents (Taxus) and everolimus-eluting stents (Xience) in left main coronary artery disease with 3 years follow-up (from the ESTROFA-LM registry).
    De la Torre Hernandez JM; Alfonso F; Sanchez Recalde A; Jimenez Navarro MF; Perez de Prado A; Hernandez F; Abdul-Jawad Altisent O; Roura G; Garcia Camarero T; Elizaga J; Rivero F; Gimeno F; Calviño R; Moreu J; Bosa F; Rumoroso JR; Bullones JA; Gallardo A; Fernandez Diaz JA; Ruiz Arroyo JR; Aragon V; Masotti M;
    Am J Cardiol; 2013 Mar; 111(5):676-83. PubMed ID: 23273715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis.
    Meng M; Gao B; Wang X; Bai ZG; Sa RN; Ge B
    BMC Cardiovasc Disord; 2016 Feb; 16():34. PubMed ID: 26860585
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of zotarolimus-eluting stents compared with sirolimus-eluting stents in patients undergoing percutaneous coronary interventions--a meta-analysis of randomized controlled trials.
    Fan J; Du H; Yin Y; Ling Z; Wu J; Xiao P; Zrenner B
    Int J Cardiol; 2013 Sep; 167(5):2126-33. PubMed ID: 22703941
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
    Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
    J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.
    Byrne RA; Kastrati A; Massberg S; Wieczorek A; Laugwitz KL; Hadamitzky M; Schulz S; Pache J; Fusaro M; Hausleiter J; Schömig A; Mehilli J;
    J Am Coll Cardiol; 2011 Sep; 58(13):1325-31. PubMed ID: 21920260
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial.
    Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW
    JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
    Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
    Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts.
    Taniwaki M; Räber L; Magro M; Kalesan B; Onuma Y; Stefanini GG; van Domburg RT; Moschovitis A; Meier B; Jüni P; Serruys PW; Windecker S
    EuroIntervention; 2014; 9(12):1432-40. PubMed ID: 24064377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials.
    Kastrati A; Dibra A; Eberle S; Mehilli J; Suárez de Lezo J; Goy JJ; Ulm K; Schömig A
    JAMA; 2005 Aug; 294(7):819-25. PubMed ID: 16106007
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register.
    Kedhi E; Gomes ME; Lagerqvist B; Smith JG; Omerovic E; James S; Harnek J; Olivecrona GK
    JACC Cardiovasc Interv; 2012 Nov; 5(11):1141-9. PubMed ID: 23174638
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
    J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paclitaxel-eluting stents versus sirolimus-eluting stents in patients with diabetes mellitus undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.
    Wang HB; Zeng P; Yang J; Yang J; Liu XW
    Intern Emerg Med; 2016 Oct; 11(7):1005-13. PubMed ID: 27631549
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
    Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.
    Stone GW; Kedhi E; Kereiakes DJ; Parise H; Fahy M; Serruys PW; Smits PC
    Circulation; 2011 Aug; 124(8):893-900. PubMed ID: 21824922
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome.
    Omar A; Torguson R; Kitabata H; Pendyala LK; Loh JP; Magalhaes MA; Satler LF; Suddath WO; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2014 Dec; 84(7):1053-60. PubMed ID: 24619969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.